Clinical Trial Update: Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting Phase 1/2 results for a topical immune modulator intended to enhance the Hepatitis B vaccine response. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Snippet

Sponsor: University of British Columbia | Conditions: Hepatitis B | Phase 1, Phase 2 | Status: COMPLETED